- Home
- MCRI vs IMCR Comparison
MCRI vs IMCR Comparison
Compare MCRI & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRI
- IMCR
- Stock Information
- Founded
- MCRI 1972
- IMCR 2008
- Country
- MCRI United States
- IMCR United Kingdom
- Employees
- MCRI N/A
- IMCR N/A
- Industry
- MCRI Hotels/Resorts
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCRI Consumer Discretionary
- IMCR Health Care
- Exchange
- MCRI Nasdaq
- IMCR Nasdaq
- Market Cap
- MCRI 1.6B
- IMCR 1.5B
- IPO Year
- MCRI 1993
- IMCR 2021
- Fundamental
- Price
- MCRI $89.40
- IMCR $29.92
- Analyst Decision
- MCRI Hold
- IMCR Buy
- Analyst Count
- MCRI 5
- IMCR 13
- Target Price
- MCRI $84.00
- IMCR $65.18
- AVG Volume (30 Days)
- MCRI 109.9K
- IMCR 146.2K
- Earning Date
- MCRI 02-11-2025
- IMCR 02-26-2025
- Dividend Yield
- MCRI 1.34%
- IMCR N/A
- EPS Growth
- MCRI 18.10
- IMCR N/A
- EPS
- MCRI 4.96
- IMCR N/A
- Revenue
- MCRI $522,186,000.00
- IMCR $296,312,000.00
- Revenue This Year
- MCRI $2.73
- IMCR $28.89
- Revenue Next Year
- MCRI $2.07
- IMCR $13.00
- P/E Ratio
- MCRI $18.02
- IMCR N/A
- Revenue Growth
- MCRI 4.13
- IMCR 25.09
- 52 Week Low
- MCRI $64.50
- IMCR $27.69
- 52 Week High
- MCRI $96.11
- IMCR $72.56
- Technical
- Relative Strength Index (RSI)
- MCRI 56.09
- IMCR 47.96
- Support Level
- MCRI $90.43
- IMCR $28.41
- Resistance Level
- MCRI $96.11
- IMCR $30.49
- Average True Range (ATR)
- MCRI 2.59
- IMCR 1.47
- MACD
- MCRI 0.22
- IMCR -0.07
- Stochastic Oscillator
- MCRI 52.28
- IMCR 41.03
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.